title: Long Noncoding RNA MALAT-1 Can Predict Poor Prognosis: A Meta-Analysis.
abstract: BACKGROUND
  MALAT-1 is a highly conserved nuclear long non-coding RNA (lncRNA). The overexpression of MALAT-1 has been reported in several types of cancers. This meta-analysis was conducted to further investigate its potential role as a prognostic indicator in various cancers.
  
  
  METHODS
  The meta-analysis was performed by use of systematic search terms in 13 databases for qualified papers on prognosis in cancer from inception to June 30, 2015. The combined hazard ratios (HRs) with 95% confidence interval (95% CI) were computed to demonstrate the effect of MALAT-1 on prognosis of cancers.
  
  
  RESULTS
  A total of 590 papers were initially identified, and 17 studies were finally included in this paper. Meta-analysis was accomplished with a total of 1626 patients. Combined HRs and 95% CI were calculated by fixed-effects or random-effects models. The quality assessment of included studies was performed by the Newcastle-Ottawa scale (NOS). High expression of MALAT-1 was found to be an indicator of poor prognosis in overall survival (OS) (HR=1.84, 95% CI: 1.27-2.67) and disease-free survival (DFS) (HR=2.37, 95% CI: 1.55-3.62). In subgroups, the associations between MALAT-1 and survival were also apparent, for instance, in country subgroup: China (HR=1.85, 95% CI: 1.14-2.99).
  
  
  CONCLUSIONS
  The overexpression of MALAT-1 may be a potential prognostic indicator for various human cancers.
authors.affiliation: Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China (mainland).
authors.forename: Ruixue
authors.initials: R
authors.lastname: Tang
authors.affiliation: Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China (mainland).
authors.forename: Mengtong
authors.initials: M
authors.lastname: Jiang
authors.affiliation: Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China (mainland).
authors.forename: Lu
authors.initials: L
authors.lastname: Liang
authors.affiliation: Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China (mainland).
authors.forename: Dandan
authors.initials: D
authors.lastname: Xiong
authors.affiliation: Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China (mainland).
authors.forename: Yiwu
authors.initials: Y
authors.lastname: Dang
authors.affiliation: Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China (mainland).
authors.forename: Gang
authors.initials: G
authors.lastname: Chen
mesh_terms: D006801:Humans; D009369:Neoplasms / Q000235:genetics*; D011379:Prognosis; D017594:Publication Bias; D062085:RNA, Long Noncoding / Q000235:genetics*; D016019:Survival Analysis
chemical_list: C557041:MALAT1 long non-coding RNA, human; D062085:RNA, Long Noncoding
references.citation: J Clin Epidemiol. 2008 Oct;61(10):991-6
references.pmid: 18538991
references.citation: Chemotherapy. 2006;52(6):301-7
references.pmid: 17008790
references.citation: Oncogene. 2003 Sep 11;22(39):8031-41
references.pmid: 12970751
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Stat Med. 1998 Dec 30;17(24):2815-34
references.pmid: 9921604
references.citation: Cell. 2009 Feb 20;136(4):629-41
references.pmid: 19239885
references.citation: Lancet Oncol. 2015 Jul;16(7):e317
references.pmid: 26051235
references.citation: Diabetes Metab. 2015 Jun;41(3):223-30
references.pmid: 25483023
references.citation: Tumour Biol. 2015 May;36(5):3355-9
references.pmid: 25613066
references.citation: Tumour Biol. 2015 Apr;36(4):2403-7
references.pmid: 25481511
references.citation: Tumour Biol. 2015 Apr;36(4):2947-55
references.pmid: 25480417
references.citation: Cancer Res. 2015 Apr 1;75(7):1322-31
references.pmid: 25600645
references.citation: Tumour Biol. 2015 Mar;36(3):1477-86
references.pmid: 25431257
references.citation: CA Cancer J Clin. 2015 Mar;65(2):87-108
references.pmid: 25651787
references.citation: J Neurooncol. 2015 Jan;121(1):101-8
references.pmid: 25217850
references.citation: Carcinogenesis. 2014 Dec;35(12):2731-9
references.pmid: 25280565
references.citation: BMC Cancer. 2014;14:809
references.pmid: 25369863
references.citation: J Cancer Res Clin Oncol. 2014 Dec;140(12):1989-95
references.pmid: 24816785
references.citation: Int J Clin Exp Pathol. 2014;7(6):3174-81
references.pmid: 25031737
references.citation: Asian Pac J Cancer Prev. 2014;15(7):2971-7
references.pmid: 24815433
references.citation: Clin Cancer Res. 2014 Mar 15;20(6):1531-41
references.pmid: 24449823
references.citation: Int J Cancer. 2014 Feb 1;134(3):622-8
references.pmid: 23832847
references.citation: J Mol Med (Berl). 2013 Jul;91(7):791-801
references.pmid: 23529762
references.citation: PLoS Genet. 2013 Mar;9(3):e1003368
references.pmid: 23555285
references.citation: Cancer Res. 2013 Feb 1;73(3):1180-9
references.pmid: 23243023
references.citation: Med Oncol. 2012 Sep;29(3):1810-6
references.pmid: 21678027
references.citation: J Thorac Oncol. 2011 Dec;6(12):1984-92
references.pmid: 22088988
references.citation: Cell. 2011 Nov 11;147(4):773-88
references.pmid: 22078878
references.citation: Int J Oncol. 2011 Jul;39(1):169-75
references.pmid: 21503572